Very precise summation Rebekah. That's pretty much the gist of it. My understanding also is, the approximately 2 billion options that expired on the 31st of August at 0.007cent goes back to the company. So it will reduce the number of shares on issue with our register. We are very fortunate that we are well funded until the 201 trial results in January 2025 and we weren't financially dependent on those options being taken up. I believe we will either have a licensing deal or partnership in place by the time January 2025 rolls around or, at absolute minimum, have a finance facility lined up based on the success criteria of the 201 trial results.
Dr Stamler certainly has his work cut out for him and time is of the essence here. He knows what is at stake and I am confident if anyone can pull this off, it is him.
Stockman.
ATH Price at posting:
0.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)